- Home
- NRK vs AUPH Comparison
NRK vs AUPH Comparison
Compare NRK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRK
- AUPH
- Stock Information
- Founded
- NRK 2002
- AUPH 1993
- Country
- NRK United States
- AUPH Canada
- Employees
- NRK N/A
- AUPH N/A
- Industry
- NRK Trusts Except Educational Religious and Charitable
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NRK Finance
- AUPH Health Care
- Exchange
- NRK Nasdaq
- AUPH Nasdaq
- Market Cap
- NRK 922.1M
- AUPH 1.1B
- IPO Year
- NRK N/A
- AUPH 1999
- Fundamental
- Price
- NRK $9.87
- AUPH $7.58
- Analyst Decision
- NRK
- AUPH Strong Buy
- Analyst Count
- NRK 0
- AUPH 2
- Target Price
- NRK N/A
- AUPH $11.50
- AVG Volume (30 Days)
- NRK 187.3K
- AUPH 1.6M
- Earning Date
- NRK 01-01-0001
- AUPH 07-31-2025
- Dividend Yield
- NRK 4.10%
- AUPH N/A
- EPS Growth
- NRK N/A
- AUPH N/A
- EPS
- NRK N/A
- AUPH 0.27
- Revenue
- NRK N/A
- AUPH $247,295,000.00
- Revenue This Year
- NRK N/A
- AUPH $12.15
- Revenue Next Year
- NRK N/A
- AUPH $18.31
- P/E Ratio
- NRK N/A
- AUPH $28.53
- Revenue Growth
- NRK N/A
- AUPH 29.20
- 52 Week Low
- NRK $8.95
- AUPH $5.20
- 52 Week High
- NRK $11.09
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- NRK 56.70
- AUPH 40.36
- Support Level
- NRK $9.86
- AUPH $7.29
- Resistance Level
- NRK $9.94
- AUPH $8.86
- Average True Range (ATR)
- NRK 0.05
- AUPH 0.34
- MACD
- NRK 0.03
- AUPH -0.06
- Stochastic Oscillator
- NRK 78.30
- AUPH 19.37
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.